Taysha Gene Therapies (TSHA) Change in Accured Expenses (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Change in Accured Expenses data on file, last reported at -$5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 142.31% year-over-year to -$5.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (up 182.28% YoY), and the FY2025 full-year result was $6.3 million, up 542.58% from the prior year.
• Change in Accured Expenses declined to -$5.1 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.0 million in Q3 2025 to a low of -$7.7 million in Q2 2022.
• A 5-year average of -$934176.5 and a median of -$747000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses sank 2453.04% in 2023 and surged 2422.64% in 2025, its largest moves.
• Tracing TSHA's Change in Accured Expenses over 5 years: stood at -$747000.0 in 2022, then plunged by 170.01% to -$2.0 million in 2023, then jumped by 105.26% to $106000.0 in 2024, then surged by 2422.64% to $2.7 million in 2025, then plunged by 292.56% to -$5.1 million in 2026.
• Business Quant data shows TSHA's Change in Accured Expenses at -$5.1 million in Q1 2026, $2.7 million in Q4 2025, and $5.0 million in Q3 2025.